Welcome to our dedicated page for Relief Therapeut news (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on Relief Therapeut stock.
The RLFTY news page on Stock Titan aggregates company-issued announcements and related coverage for RELIEF THERAPEUTICS Holding SA and the combined entity MindMaze Therapeutics Holding SA. These disclosures describe a transition from a rare-disease biopharmaceutical focus toward an integrated platform that combines digital neurotherapeutics with specialty biopharmaceutical assets.
News items include updates on Relief’s clinical pipeline, such as RLF‑TD011 for epidermolysis bullosa and RLF‑OD032 for phenylketonuria. Releases detail regulatory designations, clinical trial progress and bioequivalence results, providing insight into how the company advances candidates targeting rare dermatological, metabolic and respiratory conditions.
Another major theme in the RLFTY news flow is corporate transformation. The company has reported on a proposed and then completed business combination with NeuroX Group SA, which operates the MindMaze digital neurotherapeutics platform. Articles describe shareholder approvals, capital increases, and the renaming of the company to MindMaze Therapeutics Holding SA, as well as the subsequent listing of the combined entity under the ticker MMTX on the SIX Swiss Exchange.
Additional coverage highlights MindMaze Therapeutics’ activities, including its reimbursement strategy for digital neurorehabilitation, participation in national evidence-generation programs, and alignment with health technology assessment frameworks. These updates explain how the company positions its AI-enabled neurotherapeutics for deployment across clinics and home settings.
Investors and observers can use this news page to follow clinical milestones, regulatory interactions, reimbursement developments and key corporate events affecting RLFTY and the underlying Swiss-listed company. Regularly reviewing these items helps build a picture of how the combined business is evolving across neurology-focused digital therapeutics and rare-disease biopharmaceutical programs.
Relief Therapeutics has announced a strategic update concerning its financing efforts, opting to withdraw a prior SEC registration statement to explore non-dilutive funding options. This move aims to facilitate a potential listing on the Nasdaq. The company plans a reverse stock split, pending shareholder approval, to enhance its appeal to investors. The proposed reverse split is part of a broader initiative to improve the company's public perception and reduce the number of outstanding shares, which currently stems from past mergers. Relief is focused on treating rare diseases and aims to advance its innovative pipeline, including partnerships for metabolic disorder treatments.
Relief Therapeutics Holding announced independent IRB approval for a trial of RLF-TD011 as an adjunctive treatment for cutaneous T-cell lymphoma (CTCL). This proof-of-concept study, led by Dr. Alan Zhou at Northwestern University, aims to assess the effects of RLF-TD011, a hypochlorous acid topical spray, on CTCL lesions over an eight-week period with 30 participants. Given the challenging prognosis of CTCL, where advanced cases have a five-year survival rate of just 24%, this study represents a critical development pathway for RLF-TD011, with potential implications for FDA and EMA submissions for this unmet medical need.
Relief Therapeutics Holding SA has filed Amendment No. 2 to its Registration Statement on Form F-1 with the SEC, proposing an offering of up to 833,333,200 ordinary shares as American Depositary Shares (ADSs). The preliminary prospectus includes warrants for an additional 625,000,000 shares. Underwriters may also purchase an extra 125,000,000 shares and warrants. The terms of the offering remain uncertain, pending finalization in a future amendment. The effectiveness of the registration statement and completion of the offering are not guaranteed, affecting potential investor interest.
Relief Therapeutics and NRx Pharmaceuticals have finalized settlement agreements resolving litigation between them. Key outcomes include Relief acquiring all assets related to the aviptadil development program, including regulatory filings and clinical data. Relief will now exclusively develop and commercialize aviptadil, continuing its Right to Try Program for two years. Moreover, Relief will make milestone payments to NeuroRx for commercial approval and pay royalties, capped at $30 million. The companies have agreed not to compete in aviptadil development.
Relief Therapeutics Holding SA will present at the 15th Annual Biotech Showcase and host investor meetings on January 9-10, 2023, in San Francisco. CEO Jack Weinstein will provide insights into the company’s rare disease portfolio and commercial strategy. The Biotech Showcase presentation is scheduled for January 10 at 3:30 PM PST. The company focuses on developing novel treatments for rare diseases and holds a diverse pipeline, including products for phenylketonuria and epidermolysis bullosa.
Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) has announced an extension of its pending litigation settlement with NRx Pharmaceuticals, Inc. until November 7, 2022. This extension provides both parties additional time to finalize their tentative settlement agreement, although there are no guarantees of a successful conclusion. Relief is a biopharmaceutical company focused on developing treatments for rare diseases and has a diverse pipeline, including therapies for metabolic disorders and pulmonary indications.
Relief Therapeutics has filed Amendment No. 2 to its Form F-6 Registration Statement with the U.S. SEC to implement a reverse split of its American Depositary Receipts (ADRs), changing the ratio from 1:150 to 1:200. This change will take effect on November 3, 2022, as part of Relief's strategy to uplist its ADRs to the NASDAQ. The new ratio means that three new ADRs will be issued for every four existing ADRs. Relief aims to enhance accessibility for U.S. investors and maintain rights comparable to holders of ordinary shares.
Relief Therapeutics announced the promotion of Paolo Galfetti to Chief Operating Officer, effective October 14, 2022. Galfetti will maintain his role as CEO of APR Applied Pharma Research and continue his contributions to Relief's Board of Directors. With extensive experience in the pharmaceutical sector and a pivotal role in Relief's management since APR's acquisition, Galfetti is expected to enhance the company’s strategic initiatives, particularly the U.S. launch of PKU GOLIKE. Relief focuses on developing treatments for rare diseases, with significant ongoing projects including ACER-001 and aviptadil.
Relief Therapeutics has launched PKU GOLIKE in the U.S., a medical food for managing phenylketonuria (PKU). This launch, aided by an exclusive distributor, fulfills a milestone from the acquisition of APR Applied Pharma Research. Relief will make a milestone payment of CHF 2.8 million and issue 150 million shares, increasing its treasury by 200 million shares. Approximately 20,000 PKU patients in the U.S. require this dietary supplement for metabolic management. PKU GOLIKE offers improved patient compliance with its unique formulation, previously available in the E.U. since 2019.
Relief Therapeutics has appointed a leading national health services company as the exclusive distributor of PKU GOLIKE in the U.S. This product is a next-generation medical food developed for managing phenylketonuria (PKU) using patented Physiomimic™ technology, aimed at enhancing patient compliance. In 2023, the company plans to file for approval of APR-OD032, expanding its offerings for PKU treatment. The collaboration boosts the company's market approach and aims to improve patient access to innovative dietary solutions.